Investment Thesis
Heron Therapeutics is an early-stage pharmaceutical company with a strong gross margin (69.4%) but deteriorating profitability, with net income declining 48.7% YoY despite modest 7.4% revenue growth. The company is burning cash operationally (-$1.5M) and has minimal shareholders' equity ($9.1M) relative to total liabilities ($237.1M), creating unsustainable financial dynamics. Without near-term profitability or significant revenue acceleration, the company faces mounting dilution risk.
Strengths
- Strong gross margin of 69.4% indicates product pricing power and low manufacturing costs
- Positive revenue growth of 7.4% YoY demonstrates some market traction
- Solid short-term liquidity with current ratio of 2.53x and $26.1M cash position
Risks
- Deteriorating profitability with net income declining 48.7% YoY despite revenue growth
- Negative operating cash flow of -$1.5M indicates business is not operationally sustainable
- Critically low shareholders' equity ($9.1M) relative to liabilities ($237.1M) creates severe financial distress risk
- Operating losses of -$4.8M and negative operating margin of -13.7% show lack of near-term path to profitability
Key Metrics to Watch
- Operating cash flow trajectory toward breakeven
- Revenue acceleration rate and sales traction metrics
- Operating margin improvement and path to operating profitability
- Cash burn rate and estimated runway
- Shareholder dilution from equity financing rounds
Financial Metrics
Revenue
34.7M
Net Income
-8.1M
EPS (Diluted)
$-0.04
Free Cash Flow
-1.9M
Total Assets
246.2M
Cash
26.1M
Profitability Ratios
Gross Margin
69.4%
Operating Margin
-13.7%
Net Margin
-23.4%
ROE
-88.8%
ROA
-3.3%
FCF Margin
-5.6%
Balance Sheet & Liquidity
Current Ratio
2.53x
Quick Ratio
1.51x
Debt/Equity
0.00x
Debt/Assets
96.3%
Interest Coverage
-1.23x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-12T07:13:13.727877 |
Data as of: 2026-03-31 |
Powered by Claude AI